The promise of weight-loss drugs keeps growing
Pharmaceutical giant Eli Lilly announced last week that the highest dose of its new weight-loss drug helped people shed more than 30 percent of their body weight, on par with gastric bypass surgery. If those stunning numbers hold up, the medication could transform care for severe obesity and add yet another powerful weapon to the arsenal against chronic diseases. CommentsPopular from OpinionsHAND CURATEDOpinionAndy BeshearThis slap in the face to rural America is a chance to turn it blueNovember 24, 2025OpinionEditorial Board‘Things happen’November 18, 2025OpinionWendy R.
- ▪Pharmaceutical giant Eli Lilly announced last week that the highest dose of its new weight-loss drug helped people shed more than 30 percent of their body weight, on par with gastric bypass surgery.
- ▪If those stunning numbers hold up, the medication could transform care for severe obesity and add yet another powerful weapon to the arsenal against chronic diseases.
- ▪CommentsPopular from OpinionsHAND CURATEDOpinionAndy BeshearThis slap in the face to rural America is a chance to turn it blueNovember 24, 2025OpinionEditorial Board‘Things happen’November 18, 2025OpinionWendy R.
4 outlets in our directory ran this story, first to last over 24 hours. Coverage spans 2 points on the political spectrum — 1 centre, 2 lean right.
- ▪ The Potential for Weight Loss Drugs Keeps On Expanding — RealClear Markets
- ▪ Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even Covered — Forbes — Business
- ▪ The Promise of Weight-Loss Drugs Keeps Growing — Real Clear Politics
Washington Post — Opinions files mainly under politics. We currently carry 95 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Washington Post — Opinions |
| Canonical URL | https://www.washingtonpost.com/opinions/2026/05/24/glp-1-weight-loss-drugs-keep-growing-more-promising/ |
| Publication time | Sun, 24 May 2026 10:00:00 +0000 |
| Retrieval time | 2026-05-24T10:07:32.096Z |
| Last seen | 2026-05-24T10:07:40.412Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Nkn40WmPfF87 · 4 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Pharmaceutical giant Eli Lilly announced last week that the highest dose of its new weight-loss drug helped people shed more than 30 percent of their body weight, on par with gastric bypass surgery. If those stunning numbers hold up, the medication could transform care for severe obesity and add yet another powerful weapon to the arsenal against chronic diseases. CommentsPopular from OpinionsHAND CURATEDOpinionAndy BeshearThis slap in the face to rural America is a chance to turn it blueNovember 24, 2025OpinionEditorial Board‘Things happen’November 18, 2025OpinionWendy R. AndersonA suspicion from 2016 is becoming Democrats’ monsterNovember 17, 2025View 3 more storiesView 3 more storiesSign up
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Post — Opinions.
Discussion
0 commentsMore from Washington Post — Opinions
